<!DOCTYPE HTML>
<!--
	ZeroFour by HTML5 UP
	html5up.net | @ajlkn
	Free for personal and commercial use under the CCA 3.0 license (html5up.net/license)
-->
<html>
<head>
<title>Kidney Imaging | Longo Lab</title>
<meta name="MobileOptimized" content="width">
<meta name="HandheldFriendly" content="true">
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />

<meta name="description"
	content="We are interested in developing novel MRI contrast agents: high-relaxivity Gd-based, blood-pool contrast agents, diamagnetic CEST (iopamidol, excipients)." />
<meta name="keywords"
	content="molecular imaging, tumor, gadolinium, contrast agent, X-ray, radiographic, kidney, acidosis, metabolism, acute kidney injury, angiogenesis, MRI, magnetic resonance imaging, CEST, vascularization" />
<meta name="robots" content="noindex, nofollow">
<meta name="revisit-after" content="3 month">

<!-- imaging, x-ray, tumor -->
<!--[if lte IE 8]><script src="assets/js/ie/html5shiv.js"></script><![endif]-->
<link rel="stylesheet" href="assets/css/main.css" />
<!--[if lte IE 8]><link rel="stylesheet" href="assets/css/ie8.css" /><![endif]-->
<!--[if lte IE 9]><link rel="stylesheet" href="assets/css/ie9.css" /><![endif]-->
</head>
<body class="homepage">
	<div id="page-wrapper">

		<!-- Header -->
		<div id="header-wrapper">

			<!-- logo unito -->
			<div class="unito-logo-container">
				<img src="images/logo_unito.jpg" class="unito-logo">
				<div>
					<a href="http://www.unito.it" title="University of Torino"
						target="_blank" id="unito-logo" class="unito-logo-text"
						style="text-decoration: none";><p>University of Torino</a> <a
						href="http://www.cim.unito.it" title="Molecular Imaging Center"
						target="_blank" style="text-decoration: none"
						class="unito-logo-text";>Molecular Imaging Center
						</p>
					</a>
				</div>
			</div>


			<div class="container">

				<!-- Header -->
				<header id="header" style="margin: -30px 0 30px 0;">
					<div class="inner">

						<!-- Logo -->
						<h1>
							<a href="home.html" id="logo">DARIO LONGO LAB</a>
							<div>
								<p style="color: gray;">Imaging Tumor Microenvironment</p>

							</div>
						</h1>
						<!-- Nav -->
						<nav id="nav">
							<ul>
								<li><a href="home.html">Home</a></li>
								<li class="current_page_item"><a
									href="research_overview.html">Research</a>
									<ul>
										<li><a href="research_overview.html">Overview</a></li>
										<li><a href="research_probes.html">MRI probes</a></li>
										<li><a href="research_angiogenesis.html">Tumor
												angiogenesis</a>
										<li>
										<li><a href="research_tumor_pH.html" font
											style="text-transform: none;">TUMOR pH IMAGING</a>
										<li>
										<li><a href="research_kidney.html" font
											style="text-transform: none;">RENAL pH IMAGING</a></li>
									</ul></li>
								<li><a href="group.html">Group</a></li>
								<li><a href="publications.html">Publications</a></li>
								<li><a href="contact.html">Contact us</a></li>
							</ul>
						</nav>

					</div>
				</header>

			</div>
		</div>


		<!-- Main Wrapper -->
		<div id="main-wrapper">

			<div class="wrapper style3">
				<div class="inner">
					<section class="container box feature3">
						<div class="row">

							<article>

								<h3 font style="text-transform: none;">Imaging renal pH</h3>
								<p align="justify">
									Ischemic renal injury is a severe clinical problem in
									nephrology and the major cause of acute kidney injury (AKI).
									Hospitalized patients commonly experience AKI, which is
									strongly associated with poor prognosis and high mortality.
									Although the principal role of the kidney is the maintenance of
									acid–base balance, current imaging approaches are unable to
									assess this important parameter and clinical biomarkers are not
									robust enough in evaluating the severity of kidney damage.
									Therefore, novel noninvasive imaging approaches are needed
									to assess the acid–base homeostasis in vivo. Our lab is also actively
									involved in the <b>COST Action "PARENCHIMA"</b> 
									<a	href="http://www.cost.eu/COST_Actions/ca/CA16103"
										target="_blank"><font color="blue">CA16103 </font></a>
									(Magnetic Resonance Imaging Biomarkers for Chronic Kidney
									Disease).<br><strong> We aim to demonstrate the biological validity
									of renal pH imaging as a novel biomarker of kidney diseases.</strong>
								</p>


							</article>

							<div class="4u 12u(mobile)">

								<!-- Spotlight -->
								<section>

									<article>

										<header>
											<h3 font style="text-transform: none;">
												<font color="red">Renal pH imaging</font></a>
											</h3>
											</br>
											<p>Imaging the pH evolution in an acute kidney injury model </p>
										</header>
										<img src="images/kidney1.jpg" alt="" class="image zooming">

										<p align="justify">
											In the past years several blood pool Gd-complexes, optimized
											for the clinical scenario, have been used in pre-clinical
											settings to report on vessel architecture and on tumor vessel
											permeability. Such Gd-based complexes have, unfortunately,
											sub-optimal contrast properties when used with the recently
											developed low-field (1 Tesla) pre-clinical MRI scanners in
											addition to sub-optimal binding properties to mouse serum
											albumin. We have developed a new blood pool Gd(III)-based CA
											<a class="html"
												href="https://www.ncbi.nlm.nih.gov/pubmed/26480471"
												target="_blank"><font color="blue">[Longo et al.
													2016]</font></a>, comparing its remarkable MRI contrast properties in
											comparison to the clinically approved MS-325 (Vasovist or
											Ablavar) and to B22956/1.
										</p>
										<img src="images/kidney2.jpg" alt="" class="image zooming">
										<p align="justify">Gd-AAZTA-MADEC showed stronger binding
											affinity to HSA, higher relaxivity both with human and with
											mouse serum albumin (at 40 MHz and 37°C), as well as more
											prolonged blood circulation time with respect to the other
											CAs. These properties turned out into brightest and prolonged
											MIP angiographic images.</p>
										<footer>
											<a href="https://www.ncbi.nlm.nih.gov/pubmed/26480471"
												target="_blank" class="button alt icon fa-file-o">Continue
												Reading</a>
										</footer>
									</article>
								</section>
							</div>

							<div class="4u 12u(mobile)">

								<!-- Spotlight -->
								<section>

									<article>

										<header>
											<h3 font style="text-transform: none;">
												<font color="red">Single kidney pH imaging</font></a>
											</h3>
											<br>
											<p>Evaluation of renal pH homeostasis after ischemia reperfusion injury</p>
										</header>
										<img src="images/kidney3.jpg" alt="" class="image zooming">

										<p align="justify">
											We have developed a new blood pool Gd(III)-based CA <a
												class="html"
												href="https://www.ncbi.nlm.nih.gov/pubmed/26480471"
												target="_blank"><font color="blue">[Longo et al.
													2016]</font></a>, comparing its remarkable MRI contrast properties in
											comparison to the clinically approved MS-325 (Vasovist or
											Ablavar) and to B22956/1.
										</p>
										<img src="images/kidney4.jpg" alt="" class="image zooming">
										<p align="justify">Gd-AAZTA-MADEC showed stronger binding
											affinity to HSA, higher relaxivity both with human and with
											mouse serum albumin (at 40 MHz and 37°C), as well as more
											prolonged blood circulation time with respect to the other
											CAs. These properties turned out into brightest and prolonged
											MIP angiographic images.</p>
										<footer>
											<a href="https://www.ncbi.nlm.nih.gov/pubmed/26460826"
												target="_blank" class="button alt icon fa-file-o">Continue
												Reading</a>
										</footer>
									</article>
								</section>
							</div>

							

							


						</div>

					</section>

				</div>
			</div>
		</div>


	</div>

	<!-- Scripts -->

	<script src="assets/js/jquery.min.js"></script>
	<script src="assets/js/jquery.dropotron.min.js"></script>
	<script src="assets/js/skel.min.js"></script>
	<script src="assets/js/skel-viewport.min.js"></script>
	<script src="assets/js/util.js"></script>
	<!--[if lte IE 8]><script src="assets/js/ie/respond.min.js"></script><![endif]-->
	<script src="assets/js/main.js"></script>

</body>
</html>